BRCA2 and ovarian cancer: By pooling the outcomes of 18,396 ovarian cancer patients from 34 individual studies, we found that BRCA mutation (BRCA1/2, BRCA1 and BRCA2) carriers had significantly improved OS and PFS benefits in ovarian cancer patients.